Servier’s $1.55B Edgewise acquisition backfires after Phase 3 setback
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
French pharmaceutical group Servier has suffered a major setback just four months after completing its $1.55 billion upfront acquisition of Edgewise Therapeutics' muscular dystrophy business. Sevasemten, the centerpiece of the deal, has failed its pivotal trial in Becker
Directly affected
- EWTX Edgewise Therapeutics
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- EWQ iShares MSCI France ETF-5.8% 9d
iShares MSCI France ETF holds stocks listed in France, which this story is about (“french”).
- LLY Eli Lilly and+22.4% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- JNJ Johnson & Johnson-1.7% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- PFE Pfizer+5.5% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- MRK Merck+1.9% 18d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| EWTX | +7.24% | +3.21% | base | after close | after close | after close | after close |
| XLV | -2.31% | +0.48% | base | after close | after close | after close | after close |
| XBI | +1.67% | +0.67% | base | after close | after close | after close | after close |
| EWQ | -1.68% | -0.67% | base | after close | after close | after close | after close |
| LLY | -8.42% | +0.54% | base | after close | after close | after close | after close |
| JNJ | +1.93% | +2.66% | base | after close | after close | after close | after close |
| PFE | -1.67% | +1.73% | base | after close | after close | after close | after close |
| MRK | -2.47% | +3.37% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Servier’s $1.55B Edgewise acquisition backfires after Phase 3 setback European Biotechnology Magazine
Source: European Biotechnology Magazine
This story
| Company | When | Move | Status |
|---|---|---|---|
| EWQ | three days earlier | -0.67% | final price |
| EWQ | five days earlier | -1.68% | final price |
| EWTX | three days earlier | +3.21% | final price |
| EWTX | five days earlier | +7.24% | final price |
| JNJ | three days earlier | +2.66% | final price |
| JNJ | five days earlier | +1.93% | final price |
| LLY | three days earlier | +0.54% | final price |
| LLY | five days earlier | -8.42% | final price |
| MRK | three days earlier | +3.37% | final price |
| MRK | five days earlier | -2.47% | final price |
| PFE | three days earlier | +1.73% | final price |
| PFE | five days earlier | -1.67% | final price |
| XBI | three days earlier | +0.67% | final price |
| XBI | five days earlier | +1.67% | final price |
| XLV | three days earlier | +0.48% | final price |
| XLV | five days earlier | -2.31% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 35 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 57 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 75 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 77 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“Servier’s $1.55B Edgewise acquisition backfires after Phase 3 setback” scores 12 out of 100. The score uses 1 sources.